company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,54879521.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,7820456.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,832712.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,63532689.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,377458.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,45000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalnoncurrentassets,othernoncurrentnonoperatingassets,Other Noncurrent Nonoperating Assets,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,45000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,,totalassets,Total Assets,=,debit,usd,63955147.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,2458254.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,7115548.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,9694653.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,19268455.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,19268455.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,136826426.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-92139734.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalcommonequity,otherequity,Other Equity Adjustments,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,44686692.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,44686692.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,44686692.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q2,,2014-03-31,2014-05-15 11:24:56+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,63955147.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,49790920.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,6712244.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,329034.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,922930.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,57755128.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,359509.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,45000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalnoncurrentassets,othernoncurrentnonoperatingassets,Other Noncurrent Nonoperating Assets,+,debit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,45000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,,totalassets,Total Assets,=,debit,usd,58159637.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,2520523.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,7468794.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,6259653.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,16248970.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,16248970.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,136984480.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-95073813.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalcommonequity,otherequity,Other Equity Adjustments,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,41910667.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,41910667.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,41910667.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2014.0,Q3,,2014-06-30,2014-08-11 15:22:16+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,58159637.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,99924000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentassets,shortterminvestments,Short-Term Investments,+,debit,usd,15998000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,10508000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,2018000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,1340000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,129788000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,100000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,45000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,45000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,,totalassets,Total Assets,=,debit,usd,129933000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,5435000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,15029000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,6585000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,27049000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,27049000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,192870000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-89986000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalcommonequity,otherequity,Other Equity Adjustments,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,102884000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,102884000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,102884000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q1,,2015-03-31,2015-05-15 16:25:01+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,129933000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,13686000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentassets,shortterminvestments,Short-Term Investments,+,debit,usd,89999000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,12982000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,2325000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,1559000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,120551000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,374000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,,totalassets,Total Assets,=,debit,usd,121029000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,4783000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,13538000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,6260000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,24581000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,24581000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,194611000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-98163000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalcommonequity,otherequity,Other Equity Adjustments,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,96448000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,96448000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,96448000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q2,,2015-06-30,2015-08-11 16:21:19+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,121029000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,71979000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentassets,shortterminvestments,Short-Term Investments,+,debit,usd,24000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,12218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,7348000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,4757000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,120302000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,1803000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,111000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,111000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,,totalassets,Total Assets,=,debit,usd,122216000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,14148000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,14439000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,6000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,34587000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,34587000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,195960000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-108331000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,87629000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,87629000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,87629000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2015.0,Q3,,2015-09-30,2015-11-12 10:54:21+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,122216000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,78287000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,26526000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,7761000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,2048000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,114622000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2869000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,11116000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,94000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,11210000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,,totalassets,Total Assets,=,debit,usd,128701000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,1012000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,10295000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,19561000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,30868000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,5517000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,5517000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,36385000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,200324000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-108008000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,92316000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,92316000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,92316000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q1,,2016-03-31,2016-05-10 17:08:45+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,128701000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,75563000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,52027000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,6363000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,1546000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,135499000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2813000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,10960000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,94000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,11054000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,,totalassets,Total Assets,=,debit,usd,149366000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,1012000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,11431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,23336000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,35779000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,5753000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,5753000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,41532000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,202744000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-94910000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,107834000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,107834000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,107834000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q2,,2016-06-30,2016-08-09 16:51:28+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,149366000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,59311000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,47050000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,7106000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,5578000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,119045000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2827000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,24759000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,94000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,24853000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,,totalassets,Total Assets,=,debit,usd,146725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,1012000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,13104000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,21331000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcurrentliabilities,currentdeferredrevenue,Current Deferred Revenue,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,35447000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,5755000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,5755000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,41202000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,206480000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-82960000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-17997000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,105523000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,105523000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,105523000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2016.0,Q3,,2016-09-30,2016-11-09 16:42:43+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,146725000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,27710000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,84742000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,3015000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,8105000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,123572000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,3796000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,32660000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,24431000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,618000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,97452000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,,totalassets,Total Assets,=,debit,usd,224820000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,1012000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,19027000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,15399000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,35438000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,22555000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,22555000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,57993000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,220218000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,-2735000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-50656000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,166827000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,166827000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,166827000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q1,,2017-03-31,2017-05-08 17:30:45+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,224820000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,55385000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,53230000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,3587000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,11664000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,123866000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,3768000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,31949000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,20275000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,578000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,92545000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,,totalassets,Total Assets,=,debit,usd,220179000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,1125000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,12148000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,18680000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,31953000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,22864000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,22864000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,54817000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,225908000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,1768000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-62314000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,165362000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,165362000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,165362000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q2,,2017-06-30,2017-08-09 16:42:04+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,220179000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,97545000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,71601000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,4878000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,8130000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,182154000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,4365000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,24002000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,16502000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,124000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,80371000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,,totalassets,Total Assets,=,debit,usd,266890000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,5055000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,8902000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,20438000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,34395000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,43936000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,17482000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,61418000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,95813000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,229671000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,17199000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-75793000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,171077000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,171077000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,171077000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2017.0,Q3,,2017-09-30,2017-11-08 17:05:27+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,266890000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,95670000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,53426000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,6141000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,13583000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,168820000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,6498000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,22652000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,11477000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,106000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,73978000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,,totalassets,Total Assets,=,debit,usd,249296000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,6305000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,9353000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,13102000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,28760000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,41624000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,735000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,42359000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,71119000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,237075000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,28900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-87798000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,178177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,178177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,178177000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q1,,2018-03-31,2018-05-10 16:39:17+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,249296000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,100247000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,69403000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,6444000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,25502000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,201596000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2773000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,19302000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,9817000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,706000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,69568000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,,totalassets,Total Assets,=,debit,usd,273937000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,6250000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,18266000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,23222000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,47738000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,40468000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,40468000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,88206000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,245486000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,31559000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-91314000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,185731000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,185731000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,185731000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q2,,2018-06-30,2018-08-07 17:28:21+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,273937000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,91226000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,78461000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,7273000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,20810000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,197770000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2553000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,18702000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,9314000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,706000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,68465000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,,totalassets,Total Assets,=,debit,usd,268788000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,5000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,7544000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,22867000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,35411000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,39312000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,39312000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,74723000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,251891000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,45597000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-103423000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,194065000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,194065000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,194065000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2018.0,Q3,,2018-09-30,2018-11-01 16:48:00+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,268788000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,102139000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,63930000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,10265000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,5895000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,182229000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2333000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,17473000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,14109000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,3565000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,74890000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,,totalassets,Total Assets,=,debit,usd,259452000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,5000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,16786000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,22436000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,44222000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,36999000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,2870000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,39869000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,84091000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,262101000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,67160000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-153900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,175361000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,175361000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,175361000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q1,,2019-03-31,2019-05-07 17:06:39+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,259452000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,108128000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,60339000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,11594000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,5598000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,185659000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2258000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,16843000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,13949000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,3178000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,73713000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,,totalassets,Total Assets,=,debit,usd,261630000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,5000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,17296000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,29450000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,51746000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,35843000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,1560000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,37403000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,89149000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,267496000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,73885000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-168900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,172481000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,172481000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,172481000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q2,,2019-06-30,2019-08-08 16:50:11+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,261630000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentassets,cashandequivalents,Cash & Equivalents,+,debit,usd,117211000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentassets,accountsreceivable,Accounts Receivable,+,debit,usd,44812000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentassets,netinventory,"Inventories, net",+,debit,usd,7247000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentassets,prepaidexpenses,Prepaid Expenses,+,debit,usd,10516000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalassets,totalcurrentassets,Total Current Assets,+,debit,usd,179786000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalassets,netppe,"Plant, Property, & Equipment, net",+,debit,usd,2319000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalnoncurrentassets,goodwill,Goodwill,+,debit,usd,39743000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalnoncurrentassets,intangibleassets,Intangible Assets,+,debit,usd,16213000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalnoncurrentassets,noncurrentdeferredtaxassets,Noncurrent Deferred & Refundable Income Taxes,+,debit,usd,13997000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalnoncurrentassets,othernoncurrentassets,Other Noncurrent Operating Assets,+,debit,usd,4980000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalassets,totalnoncurrentassets,Total Noncurrent Assets,+,debit,usd,74933000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,,totalassets,Total Assets,=,debit,usd,257038000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentliabilities,shorttermdebt,Short-Term Debt,+,credit,usd,4000000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentliabilities,accountspayable,Accounts Payable,+,credit,usd,11232000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcurrentliabilities,accruedexpenses,Accrued Expenses,+,credit,usd,27127000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalliabilities,totalcurrentliabilities,Total Current Liabilities,+,credit,usd,42359000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalnoncurrentliabilities,longtermdebt,Long-Term Debt,+,credit,usd,35687000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalnoncurrentliabilities,othernoncurrentliabilities,Other Noncurrent Operating Liabilities,+,credit,usd,3227000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalliabilities,totalnoncurrentliabilities,Total Noncurrent Liabilities,+,credit,usd,38914000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalliabilitiesandequity,totalliabilities,Total Liabilities,+,credit,usd,81273000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalliabilitiesandequity,commitmentsandcontingencies,Commitments & Contingencies,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalequity,totalpreferredequity,Preferred Stock,+,credit,usd,0.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcommonequity,commonequity,Common Stock,+,credit,usd,273170000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcommonequity,retainedearnings,Retained Earnings,+,credit,usd,71495000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalcommonequity,treasurystock,Treasury Stock,+,credit,usd,-168900000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalequity,totalcommonequity,Total Common Equity,+,credit,usd,175765000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalequityandnoncontrollinginterests,totalequity,Total Preferred & Common Equity,+,credit,usd,175765000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,totalliabilitiesandequity,totalequityandnoncontrollinginterests,Total Equity & Noncontrolling Interests,+,credit,usd,175765000.0
Eagle Pharmaceuticals Inc,EGRX,549300TN20OLYTJVP152,0000827871,2019.0,Q3,,2019-09-30,2019-11-12 16:30:55+00:00,,totalliabilitiesandequity,Total Liabilities & Shareholders' Equity,=,credit,usd,257038000.0
